Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01720446
First received: October 29, 2012
Last updated: October 14, 2014
Last verified: October 2014
  Purpose

This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: semaglutide
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Time from randomisation to first occurrence of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time from randomisation to first occurrence of an expanded composite cardiovascular outcome [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Time from randomisation to each individual component of the expanded composite cardiovascular outcome [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Time from randomisation to first occurrence of all-cause death, non-fatal MI, or non-fatal stroke [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: glycosylated haemoglobin (HbA1c) [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: fasting plasma glucose [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: body weight [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: lipid profile [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: urinary albumin to creatinine ratio [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: vital signs [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Incidence during the treatment period in other treatment outcomes: hypoglycaemic events [ Time Frame: Week 0 - 143 ] [ Designated as safety issue: No ]
  • Incidence during the treatment period in other treatment outcomes: adverse events [ Time Frame: Weeks 0-143 ] [ Designated as safety issue: No ]
  • Occurrence during the treatment period in other treatment outcomes: anti-semaglutide antibodies [ Time Frame: Weeks 0-143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: patient reported outcome (PRO) [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]

Enrollment: 3297
Study Start Date: February 2013
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Semaglutide 0.5 mg Drug: semaglutide
Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Experimental: Semaglutide 1.0 mg Drug: semaglutide
Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Placebo Comparator: Semaglutide placebo 0.5 mg Drug: placebo

Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.

Administered subcutaneously (s.c., under the skin).

Placebo Comparator: Semaglutide placebo 1.0 mg Drug: placebo

Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.

Administered subcutaneously (s.c., under the skin).


  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women with type 2 diabetes mellitus
  • Age above or equal to 50 years at screening and clinical evidence of cardiovascular disease or age above or equal to 60 years at screening and subclinical evidence of cardiovascular disease
  • Anti-diabetic drug naïve, or treated with one or two oral antidiabetic drug (OADs), or treated with human Neutral Protamin Hagedorn (NPH) insulin or long-acting insulin analogue or pre-mixed insulin, both types of insulin either alone or in combination with one or two OADs
  • HbA1c above or equal to 7.0% at screening

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Use of glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide, or other) or pramlintide within 90 days prior to screening
  • Use of any dipeptidyl peptidase 4 (DPP-IV) inhibitor within 30 days prior to screening
  • Treatment with insulin other than basal and pre-mixed insulin within 90 days prior to screening - except for short-term use in connection with intercurrent illness
  • Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg diabetes ketoacidosis) within 90 days prior to screening
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Acute coronary or cerebro-vascular event within 90 days prior to randomisation
  • Currently planned coronary, carotid or peripheral artery revascularisation
  • Chronic heart failure New York Heart Association (NYHA) class IV
  • Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma
  • Personal history of non-familial medullary thyroid carcinoma
  • Screening calcitonin above or equal to 50 ng/L
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01720446

  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Clinical Trial Call Center
Birmingham, Alabama, United States, 35205-4731
Novo Nordisk Clinical Trial Call Center
Birmingham, Alabama, United States, 35216
United States, Arizona
Novo Nordisk Clinical Trial Call Center
Phoenix, Arizona, United States, 85013
United States, California
Novo Nordisk Clinical Trial Call Center
Anaheim, California, United States, 92801
Novo Nordisk Clinical Trial Call Center
Greenbrae, California, United States, 94904
Novo Nordisk Clinical Trial Call Center
Lancaster, California, United States, 93534
Novo Nordisk Clinical Trial Call Center
Los Angeles, California, United States, 90017-4006
Novo Nordisk Clinical Trial Call Center
Mission Hills, California, United States, 91345
Novo Nordisk Clinical Trial Call Center
Monterey, California, United States, 93940
Novo Nordisk Clinical Trial Call Center
Northridge, California, United States, 91325
Novo Nordisk Clinical Trial Call Center
San Ramon, California, United States, 94583
Novo Nordisk Clinical Trial Call Center
Ventura, California, United States, 93003-2824
United States, Colorado
Novo Nordisk Clinical Trial Call Center
Aurora, Colorado, United States, 80045
United States, Connecticut
Novo Nordisk Clinical Trial Call Center
Waterbury, Connecticut, United States, 06708
United States, Florida
Novo Nordisk Clinical Trial Call Center
Bradenton, Florida, United States, 34208
Novo Nordisk Clinical Trial Call Center
Crystal River, Florida, United States, 34429
Novo Nordisk Clinical Trial Call Center
Deland, Florida, United States, 32724
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32216
Novo Nordisk Clinical Trial Call Center
Melbourne, Florida, United States, 32934
Novo Nordisk Clinical Trial Call Center
Melbourne, Florida, United States, 32901
Novo Nordisk Clinical Trial Call Center
Ocala, Florida, United States, 34471
Novo Nordisk Clinical Trial Call Center
Ponte Vedra, Florida, United States, 32081
United States, Georgia
Novo Nordisk Clinical Trial Call Center
Dunwoody, Georgia, United States, 30338
Novo Nordisk Clinical Trial Call Center
Lawrenceville, Georgia, United States, 30046
United States, Illinois
Novo Nordisk Clinical Trial Call Center
Chicago, Illinois, United States, 60607
Novo Nordisk Clinical Trial Call Center
Crystal Lake, Illinois, United States, 60012
Novo Nordisk Clinical Trial Call Center
Gurnee, Illinois, United States, 60031
United States, Indiana
Novo Nordisk Clinical Trial Call Center
Michigan City, Indiana, United States, 46360
Novo Nordisk Clinical Trial Call Center
Mishawaka, Indiana, United States, 46545
United States, Kansas
Novo Nordisk Clinical Trial Call Center
Wichita, Kansas, United States, 67205
United States, Kentucky
Novo Nordisk Clinical Trial Call Center
Louisville, Kentucky, United States, 40206
Novo Nordisk Clinical Trial Call Center
Louisville, Kentucky, United States, 40213
United States, Louisiana
Novo Nordisk Clinical Trial Call Center
Monroe, Louisiana, United States, 71203
Novo Nordisk Clinical Trial Call Center
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Novo Nordisk Clinical Trial Call Center
Methuen, Massachusetts, United States, 01844
United States, Missouri
Novo Nordisk Clinical Trial Call Center
Chesterfield, Missouri, United States, 63017
Novo Nordisk Clinical Trial Call Center
Kansas City, Missouri, United States, 64111
Novo Nordisk Clinical Trial Call Center
St. Louis, Missouri, United States, 63128
Novo Nordisk Clinical Trial Call Center
St. Louis, Missouri, United States, 63141
United States, Nebraska
Novo Nordisk Clinical Trial Call Center
Omaha, Nebraska, United States, 68198-3020
Novo Nordisk Clinical Trial Call Center
Omaha, Nebraska, United States, 68114
United States, New Hampshire
Novo Nordisk Clinical Trial Call Center
Nashua, New Hampshire, United States, 03063
United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Mine Hill, New Jersey, United States, 07803
Novo Nordisk Clinical Trial Call Center
Toms River, New Jersey, United States, 08755-8050
United States, New York
Novo Nordisk Clinical Trial Call Center
Albany, New York, United States, 12206
Novo Nordisk Clinical Trial Call Center
Rochester, New York, United States, 14609
Novo Nordisk Clinical Trial Call Center
Staten Island, New York, United States, 10301-3901
Novo Nordisk Clinical Trial Call Center
West Seneca, New York, United States, 14224
United States, North Carolina
Novo Nordisk Clinical Trial Call Center
Asheboro, North Carolina, United States, 27203
Novo Nordisk Clinical Trial Call Center
Asheville, North Carolina, United States, 28801
Novo Nordisk Clinical Trial Call Center
Durham, North Carolina, United States, 27713
Novo Nordisk Clinical Trial Call Center
Greenville, North Carolina, United States, 27834
Novo Nordisk Clinical Trial Call Center
Raleigh, North Carolina, United States, 27612
Novo Nordisk Clinical Trial Call Center
Whiteville, North Carolina, United States, 28472
Novo Nordisk Clinical Trial Call Center
Wilmington, North Carolina, United States, 28401
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Cincinnati, Ohio, United States, 45219
Novo Nordisk Clinical Trial Call Center
Cleveland, Ohio, United States, 44106
Novo Nordisk Clinical Trial Call Center
Franklin, Ohio, United States, 45005
Novo Nordisk Clinical Trial Call Center
Mason, Ohio, United States, 45040-6815
Novo Nordisk Clinical Trial Call Center
Maumee, Ohio, United States, 43537
United States, Oklahoma
Novo Nordisk Clinical Trial Call Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Novo Nordisk Clinical Trial Call Center
Beaver, Pennsylvania, United States, 15009-1957
Novo Nordisk Clinical Trial Call Center
McMurray, Pennsylvania, United States, 15317
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19152
United States, South Carolina
Novo Nordisk Clinical Trial Call Center
Greer, South Carolina, United States, 29651
Novo Nordisk Clinical Trial Call Center
Myrtle Beach, South Carolina, United States, 29572-4610
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Kingsport, Tennessee, United States, 37660
Novo Nordisk Clinical Trial Call Center
Memphis, Tennessee, United States, 38163-0001
Novo Nordisk Clinical Trial Call Center
Nashville, Tennessee, United States, 37212
United States, Texas
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75231
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75390-8858
Novo Nordisk Clinical Trial Call Center
Fort Worth, Texas, United States, 76104
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77074
Novo Nordisk Clinical Trial Call Center
Irving, Texas, United States, 75061-2210
Novo Nordisk Clinical Trial Call Center
Longview, Texas, United States, 75605
Novo Nordisk Clinical Trial Call Center
Odessa, Texas, United States, 79761-5100
Novo Nordisk Clinical Trial Call Center
Plano, Texas, United States, 75075
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78228-3419
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78224
Novo Nordisk Clinical Trial Call Center
Sugarland, Texas, United States, 77478
United States, Utah
Novo Nordisk Clinical Trial Call Center
Salt Lake City, Utah, United States, 84107
United States, Vermont
Novo Nordisk Clinical Trial Call Center
South Burlington, Vermont, United States, 05403-7205
United States, Virginia
Novo Nordisk Clinical Trial Call Center
Richmond, Virginia, United States, 23219
Novo Nordisk Clinical Trial Call Center
Winchester, Virginia, United States, 22601
Novo Nordisk Clinical Trial Call Center
Winchester, Virginia, United States, 22601-3834
United States, Washington
Novo Nordisk Clinical Trial Call Center
Wenatchee, Washington, United States, 98801-2028
United States, Wisconsin
Novo Nordisk Clinical Trial Call Center
Madison, Wisconsin, United States, 53792
Algeria
Tizi Ouzou, Algeria, 16015
Argentina
Buenos Aires, Argentina, C1449AAD
Australia, New South Wales
Blacktown, New South Wales, Australia, 2148
Brazil
São Paulo, Sao Paulo, Brazil, 04025-011
Bulgaria
Sofia, Bulgaria, 1606
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3E 3P4
Denmark
Gentofte, Denmark, 2820
Germany
Hamburg, Germany, 22607
India
Mysore, Karnataka, India, 570001
Israel
Tel-Aviv, Israel, 64239
Italy
Padova, Italy, 35128
Malaysia
Seremban, Malaysia, 70300
Mexico
Aguascalientes, Mexico, 20230
Poland
Gdansk, Poland, 80-858
Russian Federation
Moscow, Russian Federation, 119881
Spain
Sevilla, Spain, 41010
Taiwan
Chiayi City, Taiwan, 600
Thailand
Bangkok, Thailand, 10700
Turkey
Istanbul, Turkey, 34722
United Kingdom
Birmingham, United Kingdom, B9 5SS
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01720446     History of Changes
Other Study ID Numbers: NN9535-3744, 2012-002839-28, U1111-1131-7227
Study First Received: October 29, 2012
Last Updated: October 14, 2014
Health Authority: Algeria: Ministry of Health
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia
Australia: Department of Health and Ageing Therapeutic Goods Administration
Brazil: National Health Surveillance Agency
Bulgaria: Ministry of Health
Canada: Public Health Agency of Canada
Denmark: Danish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
India: Ministry of Health
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: The Italian Medicines Agency
Malaysia: Ministry of Health
Mexico: National Institute of Public Health, Health Secretariat
Poland: Ministry of Health and Social Security
Russia: Ministry of Health of the Russian Federation
Spain: Spanish Agency of Medicines and Health Care Products
Taiwan: Department of Health
Thailand: Ministry of Public Health
Turkey: Ministry of Health Drug and Pharmaceutical Department
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 23, 2014